---
created: '2026-02-13T17:51:33.734130Z'
description: In a randomized, placebo-controlled, double-blind trial, NMN supplementation
  (250 mg/day for 10 weeks) increased skeletal muscle insulin sensitivity, insulin
  signaling, and muscle remodeling in postmenopausal prediabetic women. This represents
  a significant translational study demonstrating NAD+ precursor efficacy in human
  metabolic dysfunction.
dg-home: false
dg-publish: true
gardenUsername: dev_admin
permalink: /garden/dev_admin/research/nmn-improves-muscle-insulin-sensitivity-in-prediabetic-women/
slug: nmn-improves-muscle-insulin-sensitivity-in-prediabetic-women
tags:
- research
- NMN
- NAD+
- insulin sensitivity
- skeletal muscle
- aging
- prediabetes
- clinical trial
templateEngineOverride: njk
title: NMN improves muscle insulin sensitivity in prediabetic women
type: research
updated: '2026-02-13T17:51:33.734130Z'
---

{% raw %}
<h1>NMN improves muscle insulin sensitivity in prediabetic women</h1>
<h2>Study Information</h2>
<p><strong>Authors</strong>: Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, Sindelar M, Pietka T, Patterson BW, Imai SI, Klein S<strong>Journal</strong>: Science<br />
<strong>Publication Date</strong>: 2021-06-11<br />
<strong>Type</strong>: Clinical Trial<br />
<strong>Study Design</strong>: Randomized Controlled Trial<strong>Citations</strong>: 520<strong>DOI</strong>: <a href="https://doi.org/10.1126/science.abe9985">10.1126/science.abe9985</a><strong>PMID</strong>: <a href="https://pubmed.ncbi.nlm.nih.gov/33888596/">33888596</a><strong>PMC</strong>: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550608/">PMC8550608</a><strong>Semantic Scholar</strong>: <a href="https://www.semanticscholar.org/paper/PMID:33888596">View</a></p>
<h2>Abstract</h2>
<p>In a randomized, placebo-controlled, double-blind trial, NMN supplementation (250 mg/day for 10 weeks) increased skeletal muscle insulin sensitivity, insulin signaling, and muscle remodeling in postmenopausal prediabetic women. This represents a significant translational study demonstrating NAD+ precursor efficacy in human metabolic dysfunction.</p>
<h2>Keywords</h2>
<p>NMN, NAD+, insulin sensitivity, skeletal muscle, aging, prediabetes, metabolic health, SIRT1</p>
<!-- NEO4J_CONTENT_START -->
<h2>Relationships</h2>
<p>No relationships found.</p>
<!-- NEO4J_CONTENT_END -->
<h2>Methodology</h2>
<pre><code class="language-yaml">'{&quot;blinding&quot;: &quot;Double-blind (participants and investigators)&quot;, &quot;design&quot;: &quot;Randomized,
  placebo-controlled, double-blind trial&quot;, &quot;intervention&quot;: &quot;250 mg/day NMN or placebo
  for 10 weeks&quot;, &quot;randomization&quot;: &quot;Computer-generated randomization sequence&quot;}'
</code></pre>
<h3>Study Design</h3>
<ul>
<li><strong>Sample Size</strong>: n=25- <strong>Duration</strong>: 10 weeks#### Population Characteristics</li>
</ul>
<pre><code class="language-yaml">'{&quot;age_range&quot;: &quot;55-75 years&quot;, &quot;gender&quot;: &quot;Female (postmenopausal)&quot;, &quot;health_status&quot;:
  &quot;Prediabetic, overweight or obese&quot;, &quot;inclusion_criteria&quot;: [&quot;BMI 25-40 kg/m2&quot;, &quot;Prediabetic
  (HbA1c 5.7-6.4%)&quot;, &quot;Postmenopausal&quot;]}'
</code></pre>
<h2>Results</h2>
<h3>Key Findings</h3>
<pre><code class="language-yaml">'{&quot;primary&quot;: [{&quot;measure&quot;: &quot;Hyperinsulinemic-euglycemic clamp&quot;, &quot;name&quot;: &quot;Muscle insulin
  sensitivity&quot;, &quot;p_value&quot;: 0.007, &quot;result&quot;: &quot;25% improvement in glucose disposal rate&quot;}],
  &quot;secondary&quot;: [{&quot;name&quot;: &quot;Muscle NAD+ content&quot;, &quot;result&quot;: &quot;Increased but not statistically
  significant&quot;}, {&quot;name&quot;: &quot;Insulin signaling (AKT phosphorylation)&quot;, &quot;result&quot;: &quot;Significantly
  increased&quot;}, {&quot;name&quot;: &quot;Muscle remodeling gene expression&quot;, &quot;result&quot;: &quot;Upregulated&quot;}]}'
</code></pre>
<h3>Statistical Analysis</h3>
<h4>Statistical Significance</h4>
<pre><code class="language-yaml">'{&quot;adjustment&quot;: &quot;None required (single primary outcome)&quot;, &quot;primary_outcome&quot;: &quot;p =
  0.007 for glucose disposal rate&quot;}'
</code></pre>
<h4>Effect Sizes</h4>
<pre><code class="language-yaml">'{&quot;confidence_interval&quot;: &quot;95% CI: 8-42%&quot;, &quot;glucose_disposal&quot;: &quot;25% improvement (NMN
  vs placebo)&quot;}'
</code></pre>
<h2>Limitations</h2>
<ul>
<li>Small sample size (n=25)</li>
<li>Female-only cohort limits generalizability</li>
<li>Short duration (10 weeks)</li>
<li>Single dose tested (250 mg/day)</li>
<li>No long-term follow-up</li>
</ul>
<h2>Research Integrity</h2>
<h3>Funding Sources</h3>
<ul>
<li>National Institutes of Health (NIH)</li>
<li>Nutrition Obesity Research Center (Washington University)</li>
</ul>
<h3>Conflicts of Interest</h3>
<ul>
<li>S.I. Imai is co-inventor of patents related to NMN</li>
</ul>
<h2>Replication Status</h2>
<p>Partially replicated by subsequent studies (PMID: 35441613)</p>
<h2>References</h2>
<ul>
<li>Rajman L et al. Cell Metab. 2018;27(3):529-547. PMID: 29514064</li>
<li>Yoshino J et al. Cell Metab. 2011;14(4):528-536. PMID: 21982712</li>
<li>Cant√≥ C et al. Cell Metab. 2012;15(6):838-847. PMID: 22682224</li>
</ul>
<h2>Source Data</h2>
<ul>
<li><strong>Source System:</strong> PubMed - <strong>Last Modified in Source:</strong> 2026-01-25T21:22:09.479810+00:00</li>
</ul>

{% endraw %}